Curis Inc. Receives Nasdaq Delisting Notice, Plans Appeal to Avoid Suspension
CRIS sits 20% above its 52-week low of $0.49 on light trading volume (0.3× avg).
Summary
Curis Inc. has officially received a delisting determination letter from Nasdaq due to its common stock failing to meet the minimum $1.00 bid price requirement, with trading suspension set for May 6, 2026, pending an appeal.
Key Events · Legal and Risk Events · CRIS
-
Official Delisting Notice Received
Curis Inc. received a Delist Determination Letter from Nasdaq on April 27, 2026, due to its common stock closing below the minimum $1.00 bid price for 30 consecutive business days.
-
Trading Suspension Imminent
The company's securities are scheduled for delisting from the Nasdaq Capital Market and suspension of trading at the opening on May 6, 2026.
-
Company Plans to Appeal
Curis Inc. intends to make a timely request for a new hearing with the Nasdaq Hearings Panel, which will stay further delisting actions, though success is not assured.
-
Prior Monitoring Accelerated Delisting
This delisting follows a period under a Discretionary Panel Monitor, which precluded the company from receiving a compliance plan or additional time to regain compliance.
Analysis · CRIS · Life Sciences
This 8-K confirms the formal delisting notice from Nasdaq, a critical development for Curis Inc. The company's stock has consistently traded below the $1.00 minimum bid price, triggering the delisting process. This event follows a prior disclosure where the company was placed under a Discretionary Panel Monitor, indicating a heightened risk of delisting for any further non-compliance. While the company intends to appeal, there is no guarantee of success, which could lead to a significant loss of liquidity and investor confidence. This further compounds the "going concern" doubts previously disclosed in their 10-K, signaling severe operational and financial challenges.
At the time of this filing, CRIS was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.7M. The 52-week trading range was $0.49 to $3.13. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.